Cargando…
A Case of Drug-Induced Hepatitis due to Bortezomib in Multiple Myeloma
We report on a case of severe hepatotoxicity in a 52-year-old male with multiple myeloma (MM) who had received bortezomib therapy. At patient presentation, liver enzymes were normal, but started to markedly increase 3 days after the patient's second dose of bortezomib was administered, when fre...
Autores principales: | Kim, Youngwoon, Kim, Ka Young, Lee, Su Hyun, Chung, Yoon Yung, Yahng, Seung-Ah, Lee, Sung-Eun, Park, Gyeongsin, Min, Chang-Ki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Immunologists
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422711/ https://www.ncbi.nlm.nih.gov/pubmed/22916049 http://dx.doi.org/10.4110/in.2012.12.3.126 |
Ejemplares similares
-
Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness
por: Jung, Seung-Hyun, et al.
Publicado: (2022) -
Skin Graft-versus-host Disease Following Autologous Stem Cell Transplantation for Multiple Myeloma
por: Lee, Sung-Eun, et al.
Publicado: (2013) -
Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014) -
Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
por: Lee, Se Ryeon, et al.
Publicado: (2019) -
Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2013)